Alane P. Barnes - 13 May 2026 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Reporting relationship: Chief Legal Officer
Issuer ticker: BCRX
Reported as of: 13 May 2026
Net transaction value: -$596,250
SEC form: 4
Accepted by SEC: 15 May 2026, 16:08:01 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Alane P. Barnes

Key filing fact

Alane P. Barnes filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 15 May 2026.

Key facts

This page summarizes Alane P. Barnes's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 May 2026, 16:08.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: -$596,250.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001584348 Primary reporting owner

Barnes Alane P

Relationship: Chief Legal Officer
Address: 4505 EMPEROR BLVD., SUITE 200, DURHAM
Signature: /s/ Alane P. Barnes
Signature date: 15 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +62,500
Change %: +16%
Price: $5.04^*
Shares after: 463,203
Date: 13 May 2026
Ownership: Direct
Footnotes: F1

BCRX transaction

Common Stock

Sale

Transaction value: $596,250
Shares: -62,500
Change %: -13%
Price: $9.54
Shares after: 400,703
Date: 13 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCRX transaction Derivative

Emp. Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -62,500
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 13 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62,500
Exercise price: $5.04
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Footnote F2

The option grant became exercisable at the rate of 25% on each of the first, second, third, and fourth anniversaries of the date of grant.